NUT carcinoma (midline carcinoma with NUTM1 rearrangement)
Prepared with OnCo (onco.cc/prep/nut-carcinoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
12 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example NUT immunohistochemistry, NUTM1 fusion by FISH or RNA sequencing, Fusion partner, Site), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (localised), which of the standard options do you recommend and why?
- 6.Am I a candidate for Ifosfamide, Cisplatin, and what side effects should I expect?
- 7.For my situation (advanced or relapsed), which of the standard options do you recommend and why?
- 8.Are there clinical trials I could join, for example of ZEN-3694, ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2), ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1), Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)?
- 9.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 10.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 11.I read that “Misdiagnosis and delay: NUT immunohistochemistry should be routine in poorly differentiated midline tumours”. How does that affect my plan?
- 12.I read that “BET inhibitor responses are short: degraders, CDK9 and HDAC combinations, and chemotherapy combinations are in trials”. How does that affect my plan?
The words I may hear
- Gene fusion: A gene fusion is two genes broken and joined together, creating a hybrid protein that can drive cancer.
- Rare cancers: Rare cancers are those with fewer than about 6 new cases per 100,000 people per year.
Tests and results to bring
Biomarker results to ask for: NUT immunohistochemistry (C52 antibody, nuclear speckled), NUTM1 fusion by FISH or RNA sequencing, Fusion partner (non-BRD4 partners associated with longer survival in the registry), Site (thoracic vs non-thoracic).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Localised: Multimodality: complete resection where feasible, radiotherapy, and intensive chemotherapy (ifosfamide-based or platinum-based, often Ewing-type regimens); early referral to a centre with NUT carcinoma experience. (Ifosfamide, Cisplatin, IMRT / IGRT (modern external beam))
- Advanced or relapsed: Clinical trial of a BET inhibitor (ZEN-3694, NUV-868, molibresib) alone or with chemotherapy; palliative chemotherapy and radiotherapy. (Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.